Thus, due to its inhibitory effects on multiple checkpoints in immunocytes and because of the relatively tolerable effects of Cbl-b deficiency on autoimmune-related hazards, Cbl-b has become an attractive cancer immunotherapy target and is being exploited in a large number of preclinical studies and clinical trials [27,41] (Supplementary Table S1, https://clinicaltrials.gov/search?term=Cbl, accessed on 14 July 2024). This evidence concerns the gene CBL and cancer.